Motor Evoked Potential-A Pilot Study Looking at Reliability and Clinical Correlations in Multiple Sclerosis
- PMID: 36943437
- PMCID: PMC11060055
- DOI: 10.1097/WNP.0000000000001003
Motor Evoked Potential-A Pilot Study Looking at Reliability and Clinical Correlations in Multiple Sclerosis
Abstract
Purpose: Multiple sclerosis (MS) is a clinically heterogeneous disease. Biomarkers that can assess pathological processes that are unseen with conventional imaging remain an unmet need in MS disease management. Motor evoked potentials (MEPs) could be such a biomarker. To determine and follow longitudinal MEP reliability and correlations with clinical measures in MS patients.
Methods: This is a single-center study in alemtuzumab-treated MS patients to evaluate temporal reliability of MEPs, identify MEP minimum detectible differences, and explore correlations with existing clinical scales. Ten MS patients recently treated with alemtuzumab were evaluated every 6 months over 3 years. Clinical evaluations consisted of expanded disability status scale, timed 25-foot walk, 6-minute walk, and nine-hole peg test. MEPs were measured twice, 2 weeks apart, every 6 months.
Results: Eight patients completed all 3 years of study. The intraclass correlation coefficient for MEP parameters ranged from 0.76 to 0.98. TA latency and amplitude with facilitation significantly and strongly correlated with all clinical measures, whereas the MEP duration modestly correlated. Biceps latency with facilitation significantly and moderately correlated with 9-hole peg test. Longitudinal correlations demonstrated good predictive values for either clinical deterioration or improvement.
Conclusions: MEPs have excellent intrapatient and intrarater reliability, and TA MEPs significantly and strongly correlated with expanded disability status scale, 6-minute walk, and timed 25-foot walk, whereas biceps MEPs significantly and moderately correlated with nine-hole peg test. Further studies using larger cohorts of MS patients are indicated.
Clinical trial registration: ClinicalTrials.gov, Identifier: NCT02623946.
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Clinical Neurophysiology Society.
Conflict of interest statement
The authors declare there are no conflicts of interest.
Figures
References
-
- Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002;15:239–245. PMID: 12045719. - PubMed
-
- Skeen MB. Changing paradigms and unmet needs in multiple sclerosis: the role of clinical neurophysiology. J Clin Neurophysiol 2021;38:162–165. - PubMed
-
- Institute of Medicine (US). In: Micheel CM, Ball JR, eds. Committee on qualification of biomarkers and surrogate endpoints in chronic disease. Evaluation of biomarkers and surrogate endpoints in chronic disease. Washington (DC): National Academies Press (US), 2010. - PubMed